Amylin-receptor pathway / satiety · Peptide
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
The guide reports investigational human obesity / metabolic development.
Context: Primary trial identifier, route and numeric dose not supplied in this entry.
Limitations: No self-directed protocol assigned; trial-specific data are needed.
Administration reported for this specific study or labeled indication.
Context: Adults with obesity or qualifying overweight without type 2 diabetes
Human study regimen: Amount: Fixed 1, 3, 6 or 9 mg; separate 6 to 9 mg and 3 to 9 mg escalation arms; Route: Subcutaneous; Frequency: Once weekly; Duration: 48 weeks; Species: Human; Population: Adults with obesity or qualifying overweight without type 2 diabetes
Limitations: Randomized dose-finding trial. Escalation intervals were not extracted.
Open this exact record in the library →Suggest a correctionThese compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.